Identifie

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science

- Journal Article Also Demonstrates the Promise of Anacor'sBoron-Based Chemistry in Developing Antibiotics - PALO ALTO, Calif., June 21, 2007 /PRNewswire/ -- AnacorPharmaceuticals, a privately held pharmaceutical company, announcedtoday that the journal Science will publish results of researchthat details how AN2690, the company's lead clinical candidate,kills fungal cells by interfering...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with itsBruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...

NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking

BETHESDA, Md., April 2, 2007--Scientists supported by theNational Institute on Drug Abuse (NIDA), part of the NationalInstitutes of Health, have for the first time identified genes thatmight increase a person's ability to abstain from smoking. Thebreakthrough research was conducted by Dr. George Uhl at NIDA'sIntramural Re...

Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity

Rigel Program to be Presented at Keystone Scientific Meeting SOUTH SAN FRANCISCO, Calif., March 27, 2007/PRNewswire-FirstCall/ -- Rigel today announced that YonchuJenkins, Ph.D., Associate Director of Virology, will be presentingon the company's efforts to develop a small molecule therapeutic totreat patients with the Human Immunodeficiency Virus (HIV)infection at the Keystone Symposium i...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of skin. Fisher's study shows that inaddition to i...